AbbVie (NYSE: ABBV) is a drug company, which was spun off from Abbott in early 2013. It strives to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio.
Why Should Investors Book Profit?
- Weak liquidity profile: In Q3 FY21, the company's current ratio was 1.01x compared to the industry median of 6.43x, while the quick ratio stood at 0.91x compared to the industry median of 4.20x. These lower ratios against the industry indicates that the company's short-term obligations are growing faster than its resources to cover them, which is not a good indication.
- Heavily leveraged: The company’s debt to equity ratio at the end of September 30, 2021, stood at 5.96x, which is too high against the industry median. Additionally, its % LT Debt to Total Capital stood at 78.5% against the industry median of 0.2%. These factors imply higher balance sheet risks.
- Higher Cash Cycle days: The company is holding higher Cash Cycle (Days) compared to the industry, implying the company takes more days to convert its inventory to cash. Currently, its Cash Cycle is at 128.8 days compared to an industry median of 71.5 days.
- Stretched valuations: ABBV shares are available at an NTM EV/Sales multiple of 4.9x compared to the industry (Pharmaceuticals) median of 2.7x, while on NTM EV/EBITDA multiple, it is trading at 9.3x compared to the industry median of 5.8x. This implies that the shares are overvalued against the industry. The stock is trading at stretched valuations on multiple parameters. Higher valuations against an industry draws a caution line.
Source: REFINITIV, Analysis by Kalkine Group
Valuation Methodology (Illustrative): EV to Sales
Analysis by Kalkine group
Stock recommendation
The company continued to achieve strong results, with double-digit operational sales and EPS growth driven by a well-balanced portfolio. Despite the strong figures, the company failed to outperform on a number of key financial metrics that are critical to its long-term success. In Q3 2021, the company reported a poor liquidity profile, against an industry accompanied with longer cash cycle days. Even a higher debt profile indicates that the balance sheet is in jeopardy. Furthermore, on an NTM basis, the stock is trading at a premium to the industry on multiple parameters. Higher valuations versus an industry cast a shadow of doubt on investors' minds. In addition, technical indicators suggest that the stock price may consolidate or may make a correction from here. Hence, considering the aforesaid rationales, we have given a “Sell” recommendation in the stock at the current market price of USD 132.56 at 9:45 am Toronto Time on January 24, 2022.
One-Year Technical Price Chart (as on January 24, 2022). Source: REFINITIV, Analysis by Kalkine Group
*The reference data in this report has been partly sourced from REFINITIV.
Disclaimer - This report has been issued by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and prepared by Kalkine and its related bodies corporate authorised to provide general financial product advice. Kalkine.com.au and associated pages are published by Kalkine.
Any advice provided in this report is general advice only and does not take into account your objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your objectives, financial situation and needs before acting upon it.
There may be a Product Disclosure Statement, Information Statement or other offer document for the securities or other financial products referred to in Kalkine reports. You should obtain a copy of the relevant Product Disclosure Statement, Information Statement or offer document and consider the statement or document before making any decision about whether to acquire the security or product.
You should also seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice in this report or on the Kalkine website. Not all investments are appropriate for all people.
The information in this report and on the Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of information contained in its reports, newsletters and websites. All information represents our views at the date of publication and may change without notice.
Kalkine does not guarantee the performance of, or returns on, any investment. To the extent permitted by law, Kalkine excludes all liability for any loss or damage arising from the use of this report, the Kalkine website and any information published on the Kalkine website (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine hereby limits its liability, to the extent permitted by law, to the resupply of services.
Please also read our Terms & Conditions and Financial Services Guide for further information.
On the date of publishing this report (referred to on the Kalkine website), employees and/or associates of Kalkine and its related entities do not hold interests in any of the securities or other financial products covered on the Kalkine website unless those persons comply with certain safeguards, procedures, and disclosures.
Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.